Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference, Highlighting Progress on Concussion Treatment

Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on neurological therapeutics, announced it will present and host one-on-one meetings with investors at Sidoti’s Micro-Cap Virtual Investor Conference scheduled for May 20-21, 2026. The company’s presentation is set for 3:15 p.m. ET on May 21, 2026, with additional virtual one-on-one meetings planned throughout the conference. For more details, the full press release is available at https://ibn.fm/MLd0Y.

The announcement underscores Oragenics’ progress in advancing its lead candidate, ONP-002, a potential first-in-class treatment for concussion and mild traumatic brain injury (mTBI). The company is preparing to commence clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. This development is significant given the high prevalence of concussions, affecting millions annually, and the lack of approved pharmacological treatments for acute mTBI. If successful, ONP-002 could fill a critical gap in neurological care.

Oragenics’ proprietary intranasal delivery technology is central to its approach, enabling targeted delivery of therapeutics to the brain. Beyond concussion, the platform holds potential for treating other neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders. The company’s strategy leverages this platform to address multiple high-unmet-need indications, which could broaden its market impact and attract investor interest.

The Sidoti conference provides a platform for Oragenics to engage with investors and highlight its clinical milestones. The one-on-one meetings offer an opportunity for deeper discussions on the company’s pipeline and regulatory strategy. As a micro-cap stock, Oragenics may benefit from increased visibility among institutional and retail investors focused on early-stage biotech opportunities.

Investors should note that the latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN. The conference presentation could serve as a catalyst for the stock, depending on the details shared regarding trial timelines and data.

Overall, Oragenics’ participation in the Sidoti conference highlights its commitment to advancing its neurological pipeline. The implications of this announcement extend beyond the conference itself, reflecting the company’s strategic progress toward clinical milestones that could transform concussion care and potentially address other neurological disorders. For a company with a market cap typical of micro-cap biotechs, such visibility is crucial for funding and partnership opportunities.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference, Highlighting Progress on Concussion Treatment.

The post Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference, Highlighting Progress on Concussion Treatment appeared first on citybuzz.